ID   UM-UC-3-LuL-2
AC   CVCL_VL58
SY   LuL-2; Luciferase Lung metastasis-2
DR   cancercelllines; CVCL_VL58
DR   Wikidata; Q98134085
RX   PubMed=21482678;
RX   PubMed=29732388;
CC   Population: Caucasian.
CC   Characteristics: Produced after passage of UM-UC-3-LuL-1 into nude mice.
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Gln2800fs*6 (c.8400delG); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 14446; PARD3B; Unexplicit; Ex9-18del; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Phe113Cys (c.338T>G); ClinVar=VCV000634690; Zygosity=Homozygous (from parent cell line).
CC   Genetic integration: Method=Transfection/transduction; Gene=UniProtKB; P08659; Firefly luciferase.
CC   Genetic integration: Method=Transfection/transduction; Gene=UniProtKB; P13249; S.alboniger pac (PuroR).
CC   Derived from site: In situ; Urinary bladder; UBERON=UBERON_0001255.
DI   NCIt; C4912; Bladder carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_VL57 ! UM-UC-3-LuL-1
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 07-09-18; Last updated: 10-09-24; Version: 11
//
RX   PubMed=21482678; DOI=10.1158/0008-5472.CAN-11-0519; PMCID=PMC4283788;
RA   Overdevest J.B., Thomas S., Kristiansen G., Hansel D.E., Smith S.C.,
RA   Theodorescu D.;
RT   "CD24 offers a therapeutic target for control of bladder cancer
RT   metastasis based on a requirement for lung colonization.";
RL   Cancer Res. 71:3802-3811(2011).
//
RX   PubMed=29732388; DOI=10.3233/BLC-180167; PMCID=PMC5929350;
RA   Zuiverloon T.C.M., de Jong F.C., Costello J.C., Theodorescu D.;
RT   "Systematic review: characteristics and preclinical uses of bladder
RT   cancer cell lines.";
RL   Bladder Cancer 4:169-183(2018).
//